TALPHERA, INC. Debt Securities, Available-for-sale, Amortized Cost
TALPHERA, INC. (TLPH) had Debt Securities, Available-for-sale, Amortized Cost of $35.43 million as of 2021-09-30, per its 10-Q filed 2021-11-15.
Discontinued › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2021-11-15
- 2021-09-30: Debt Securities, Available-for-sale, Amortized Cost $35.43M.
- 2020-12-31: Debt Securities, Available-for-sale, Amortized Cost $15.61M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2021-09-30 | $35.43M 10-Q · filed 2021-11-15 |
| 2020-12-31 | $15.61M 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |